Canaccord Genuity set a $50.00 target price on Aerie Pharmaceuticals Inc. (NASDAQ:AERI) in a research report sent to investors on Wednesday morning. The firm currently has a a buy rating on the stock.

Analyst Recommendations for Aerie Pharmaceuticals (NASDAQ:AERI)

A number of other equities analysts have also commented on the stock. Brean Capital set a $48.00 price target on shares of Aerie Pharmaceuticals and gave the stock a buy rating in a report on Thursday, September 15th. Needham & Company LLC restated a buy rating and issued a $52.00 target price (up previously from $45.00) on shares of Aerie Pharmaceuticals in a report on Thursday, September 15th. Stifel Nicolaus boosted their target price on shares of Aerie Pharmaceuticals from $40.00 to $50.00 and gave the company a buy rating in a report on Thursday, September 15th. Zacks Investment Research upgraded shares of Aerie Pharmaceuticals from a hold rating to a strong-buy rating and set a $20.00 target price on the stock in a report on Monday, July 4th. Finally, Royal Bank Of Canada boosted their target price on shares of Aerie Pharmaceuticals from $51.00 to $55.00 and gave the company an outperform rating in a report on Thursday, September 15th. One equities research analyst has rated the stock with a hold rating and eight have given a buy rating to the company’s stock. The stock currently has an average rating of Buy and an average target price of $47.56.

Aerie Pharmaceuticals (NASDAQ:AERI) opened at 34.12 on Wednesday. The company’s market cap is $951.68 million. The firm’s 50-day moving average price is $20.33 and its 200-day moving average price is $16.95. Aerie Pharmaceuticals has a 12-month low of $10.82 and a 12-month high of $35.32.

Aerie Pharmaceuticals (NASDAQ:AERI) last posted its earnings results on Wednesday, August 3rd. The company reported ($0.72) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.74) by $0.02. Equities research analysts forecast that Aerie Pharmaceuticals will post ($2.77) earnings per share for the current fiscal year.

In related news, major shareholder Foresite Capital Fund Ii, L.P. purchased 250,000 shares of the firm’s stock in a transaction on Friday, July 22nd. The stock was purchased at an average cost of $17.50 per share, with a total value of $4,375,000.00. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. 8.77% of the stock is currently owned by company insiders.

Several large investors have recently bought and sold shares of AERI. Jennison Associates LLC increased its stake in Aerie Pharmaceuticals by 0.6% in the second quarter. Jennison Associates LLC now owns 3,711,695 shares of the company’s stock valued at $65,326,000 after buying an additional 21,505 shares during the last quarter. Deerfield Management Co. increased its stake in Aerie Pharmaceuticals by 225.9% in the first quarter. Deerfield Management Co. now owns 2,632,482 shares of the company’s stock valued at $32,011,000 after buying an additional 1,824,607 shares during the last quarter. Adage Capital Partners GP L.L.C. increased its stake in Aerie Pharmaceuticals by 3.7% in the second quarter. Adage Capital Partners GP L.L.C. now owns 2,100,000 shares of the company’s stock valued at $36,960,000 after buying an additional 75,000 shares during the last quarter. Vanguard Group Inc. increased its stake in Aerie Pharmaceuticals by 11.1% in the second quarter. Vanguard Group Inc. now owns 1,006,552 shares of the company’s stock valued at $17,716,000 after buying an additional 100,645 shares during the last quarter. Finally, BlackRock Fund Advisors increased its stake in Aerie Pharmaceuticals by 10.5% in the second quarter. BlackRock Fund Advisors now owns 971,896 shares of the company’s stock valued at $17,105,000 after buying an additional 92,113 shares during the last quarter. 99.66% of the stock is owned by institutional investors.

About Aerie Pharmaceuticals

Aerie Pharmaceuticals, Inc is a clinical-stage pharmaceutical company. The Company is engaged in the discovery, development and commercialization of therapies for the treatment of patients with glaucoma and other diseases of the eye. The Company’s primary product candidates are Rhopressa and Roclatan.

5 Day Chart for NASDAQ:AERI

Receive News & Ratings for Aerie Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aerie Pharmaceuticals Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.